Portfolio Finder

Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells. Through viral replication within cancer cells, Abalos’ arenavirus-based drug candidates are designed to awake precise innate and adaptive immune responses and activate all relevant immune cell types against primary tumors and metastases. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos’ goal is to achieve a quantum leap in immuno-oncology.

adivo is a biotech company generating therapeutic antibodies for companion animals, addressing the medical needs in dogs, with an upside potential for a future in care for other species.
Antibody selection is based on a novel fully synthetic, dog-specific phage display library that allows de-novo identification of antibodies to select a drug candidate with optimal properties.
adivo is a spin-off from MorphoSys AG, a leading European biopharmaceutical company. The team transfers an in-depth expertise in discovery and development of human therapeutic antibodies to the veterinary market.

AdvanceCOR is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative biologic drugs in acute vascular syndromes and have completed phase 2.

ADVANOVA was founded in January 2012 by Dr. Frank Hemer, a doctor and computer scientist, and Bastian Bleisinger, a computer scientist. The company’s head office is in Erlangen at the centre of Germany’s “Medical Valley”.

Aignostics, a spin-off from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health, is pioneering computational pathology for pharmaceutical research and diagnostics. Its proprietary "Explainable AI" platform draws on research from Fraunhofer Society, Charité, and TU Berlin to overcome the typical "black-box" problem of AI in pathology. Aignostics' focus lies on developing bespoke AI models for clinical trials and CDx development.

Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (hepatocellular carcinoma, HCC).

Alentis has in-licensed platform technologies and monoclonal antibodies which are the result of more than a decade of research from the University of Strasbourg and Inserm, the French National Institutes of Health and the Mount Sinai Hospital, New York.

The portfolio is based on profound knowledge and expertise in liver disease, unique patient-derived model systems and the discovery of a novel, very fundamental mechanism of action underlying these diseases.

Alentis has lead monoclonal antibodies which show consistent compelling efficacy and safety in patient-derived cell and animal models.

Furthermore, Alentis has a proprietary discovery platform enabling fast-track discovery and development of compounds and targets that are relevant in the pathology of late stage liver disease and carcinogenesis.

Algiax Pharmaceuticals is a young, innovative research company in the field of neurological diseases with a special focus on neuropathic pain.

Altavo is a Dresden based medical technology startup founded in February 2021. Based on non-invasive radar sensing and AI algorithms for speech recognition and synthesis, Altavo is developing prosthetics to improve the rehabilitation of voiceless people, for example after laryngectomy. Compared to existing forms of speech rehabilitation, Altavo’s approach has fundamental advantages in terms voice quality, usability, and complication risks. Altavo is partnering with the Chair of Speech Technology and Cognitive Systems and the Chair of Radio Frequency Engineering at TU Dresden.

Amedrix develops & produces three dimensional implants (gel and liquid) based on collagen. Focus: treatment of articular cartilage damage in human an horse and other promising application areas. CE-mark for the cartilage repair product is granted & successfully used in patients.

The core competency of AQ Implants GmbH is the endoprosthetic reconstruction of severe and complex defects and anomalies. With the development of innovative implant systems AQ Implants GmbH provides surgeons with various surgical options to reconstruct a wide variety of defects.

Under the brand name REVISIO they offer a complete range of implants for the treatment of revision and tumour cases, from easy revision cases to modular-complex defect treatments.

Atriva Therapeutics stands for the next generation of antiviral therapies. MEK Inhibitors have high potential as truly efficacious and safe antiviral drugs to address the urgent need e.g. for a novel, broadly active influenza therapy.

AudioCure Pharma is an innovative clinical-stage pharmaceutical company focused on developing treatments for audiological and neurological disorders with a high unmet medical need.

Our small molecules have shown Proof-of-Principle in preclinical models for a range of otic disorders including hearing loss, tinnitus and electrode insertion trauma as well as Parkinson’s Disease. The safety and tolerability of AudioCure’s lead compound AC102 has been demonstrated in a first-in-human clinical trial. Currently, a Proof-of-Concept, Phase 2 clinical trial evaluating AC102’s efficacy in patients with Sudden Sensorineural Hearing Loss is underway across Europe.

Join us to make a meaningful impact on the lives of those affected by these disorders and turn incurable hearing loss into a treatable event.

Avelios Medical offers a modular software platform for the digitization of workflows in hospitals and data-driven patient care. The state-of-the-art software digitizes and optimizes all workflows in hospitals in a user-friendly manner, offering numerous innovative functions such as an automatically generated doctor's letter or intelligent input fields for the documentation of patient treatment. In addition, the software automatically generates fully structured data, enabling the direct use of data-driven use cases and AI algorithms. The company is based in Munich and was founded in 2020 by Nicolas Jakob, Dr. Sebastian Krammer and Christian Albrecht.

Modern therapeutic approaches face the challenge to combine efficacy, low undesired side effects and reasonable pricing. Therefore, drug substances become more and more complex, therapies become more personalized while overall life-cycle costs from drug discovery up to the manufacturing of the final therapeutic are on trial.
Peptides – or short proteins - represent a promising therapeutic class, and Belyntic’s PEC technology offers an innovative solution for their manufacturing. The linker-based approach enables parallel, efficient and highly selective purification and modification of chemically synthesized peptides. Belyntic offers kit products as well as cooperation projects and custom services for research institutions, custom peptide manufacturers as well as biotech and pharma companies.

Bind-X, formerly Dust BioSolutions, is an industrial biotechnology company with core expertise in the development, production and sale of innovative bio-based binders. The Bind-Tech technology platform is capable of solidify almost any permeable material while integrating additional functional properties. Bind-X products always increase the sustainability of Bind-X customers in the global mining, agriculture and construction industries.

c-LEcta is a leading biotechnology company located in Leipzig, Germany. The company has established itself as a leading player in the realisation of high-value biotechnology products for regulated markets, either as in-house development or in close cooperation with the industry. c-LEcta innovation capability delivers cost-efficient and sustainable production processes, creating growth opportunities across existing and new markets.

C-mo Medical Solutions is an award-winning Digital Health start-up that develops solutions for the diagnosis and management of cough-incident medical conditions. The company’s mission is to unravel the clinical potential of cough assessment and solve the major unmet medical needs associated with the management of chronic cough. The company was founded by Diogo Tecelão, Miguel Andrade, Filipe Valadas, Alexandra Lopes, Sara Lobo, and Nuno Neuparth, thus combining a wealth of knowledge on digital health, business development, and respiratory medicine.

Capical is the world leading company for contact-free ECG-measurement via capacitive electrodes. The main application areas are drivers state monitoring for the automotive industry and contact-free cardiac monitoring solutions for medical applications.

Cardior is focused on the development and clinical validation of ncRNA therapeutics for patients with myocardial infarction and heart failure. Cardior aims to market its products in collaboration with a strategic pharma partner after clinical proof-of-concept (POC) data.

CereGate is developing a Computer-Brain-Interface (“BCI”) platform that is already capable to successfully submit information into the human brain. The revolutionary software platform is clinically validated and allows for enhanced treatment of various neurological and psychiatric disorders. The CereGate platform is able to transmit information into the brain („Mind-Writing“), by utilizing state of the art neuromodulation technology. While focusing first on improving gait symptoms for Parkinson patients, CereGate aims to become a key enabling tech¬nology in the field of rehabilitation and (neuro)prosthetics.

ChromoTek focuses on the discovery and development of innovative fluorescent nanoprobes derived from single-chain antibodies from Camelidae (Chromobodies) for applications in research and high-content screening.

Hamburg-based COLIPI is developing an industrial biotechnological process that transforms climate-damaging CO2 and carbon-containing industrial waste into Climate Oil. This product serves as a sustainable and climate-neutral alternative to palm oil and crude oil. A patented bioreactor system is the key differentiator. The solution has the potential to become the world's fastest and, consequently, the most cost-effective CO2-transforming bioprocess. Some of the founders had initial exposure to the technology a decade ago. Since 2021, the project has been supported by EXIST, and in 2022, Philipp Arbeiter, Tyll Utesch, Jonas Heuer, and Maximilian Webers spun off COLIPI from the Technical University of Hamburg.

Computomics is a spin-off of the University of Tübingen and the Max Planck Institute for Developmental Biology. Computomics was founded in 2012, when it became clear that a breakthrough in DNA sequencing and the scientific work of its founders would also allow seed manufacturers to use state-of-the-art bioinformatics analysis. Computomics brings customers in green and white biotechnology sustainable economic success by developing stable plant varieties that contribute to a more resource-efficient agriculture that can feed our planet.
Among the co-founders are four experienced scientists (Prof. Dr. Weigel, Prof. Dr. Huson, Prof. Dr. Rätsch, Prof. Dr. Borgwardt), who assist the co-founder and Managing Director Dr. Sebastian Schultheiss in dealing with customer inquiries. In the meantime, the Tübingen-based company employs 12 people and has founded a sales company in the USA.

coramaze technologies GmbH, based in Munich, Germany and founded in 2013 as a University Hospital of Essen spin-off, is engaged in developing an innovative Mitral Valve repair system - mitramaze® - for a minimally invasive transcatheter repair of mitral regurgitation (MR).

Corimmun is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative peptide and biological drugs in indications with unmet medical needs.

Exit since June 2012.

CorTec is a young medical engineering company focusing on innovations in the field of neurotechnology. With CorTec Brain Interchange we are developing a direct interface between brain and technology.

Treatment of sustainable plaque in coronary arteries through our proprietary catheter based device.

Cultimate Foods is a cellular agriculture company that creates alternative fat ingredients for plant-based meat products. Unlike other fat alternatives, this company creates a unique lipid composition of the fat delivering authentic pork and beef flavor. The company raised more than 3 million EUR to date and is backed by strong life science investors HTGF, b.value, Life Science Valley as well as the largest foodtech funds Big Idea Venture, ProVeg International and Kale United.

Cunesoft provides pioneering online regulatory software for the life sciences and other regulated industries. The SaaS (Software as a Service) based solutions are delivered fully functional to customers and fulfill FDA, EU, ICH and GxP compliance regulations.

CustomSurg, founded in 2021, is a Spin-Off from ETH Zurich and Harvard University. The company is developing software-as-a-medical-device (SaMD) solutions for the optimal selection and placement of orthopaedic implants in the human body, thereby making surgery safer, faster, and simpler.